Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Defibrotide: Amended Phase III

GENT plans to submit a protocol amendment to FDA for an ongoing Phase III trial of defibrotide in order

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE